pyrazines has been researched along with Response Evaluation Criteria in Solid Tumors in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chavan, A; Fukuoka, K; Horobin, J; Iwasa, T; Keegan, M; Nakagawa, K; Padval, M; Shimizu, T; Takeda, M; Vaickus, L; Yoshida, T | 1 |
1 trial(s) available for pyrazines and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Asian People; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Half-Life; Humans; Male; Middle Aged; Neoplasms; Pyrazines; Response Evaluation Criteria in Solid Tumors; Sulfonamides | 2016 |